Dedicated to Conquering Heart Failure
A clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases
Acute Myocarditis
CardiolRx™ is currently being evaluated in a Phase II multi-national clinical study, the ARCHER trial, to evaluate the safety and tolerability as well as its impact on myocardial recovery, in patients presenting with acute myocarditis – an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age.
Learn More
Recurrent Pericarditis
Cardiol has received IND authorization from the U.S. FDA to conduct a Phase II open-label pilot study designed to evaluate the tolerance, safety, and disease endpoints of CardiolRx™ in patients with recurrent pericarditis – the most common of pericardial diseases with symptoms that include debilitating chest pain, shortness of breath, and fatigue.
Learn More
Heart Failure
Cardiol is developing a subcutaneous formulation of cannabidiol targeting the inflammation and fibrosis associated with the development and progression of heart failure – a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the U.S. exceeding $30 billion annually.
Learn More
LATEST NEWS
All News
Press Release
Cardiol Therapeutics Announces First Patient Enrolled in Phase II Study Evaluating CardiolRx™ for the Treatment of Recurrent Pericarditis
January 17, 2023
Cardiol Therapeutics Announces First Patient Enrolled in Phase II Study Evaluating CardiolRx™ for the Treatment of Recurrent Pericarditis
TSX:CRDL NASDAQ:CRDL
